Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYOBLOC for Troublesome Sialorrhea in Adults
NCT01994109Phase 3Completed
- Sponsor
- US WorldMeds
- Start
- Nov 2013
- Primary completion
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type b in sialorrhea (3 arms), sponsored by US WorldMeds. Primary endpoints: Unstimulated Salivary Flow Rate at 4 weeks and Clinical Global Impression Change at 4 weeks. Started Nov 2013; status: completed.
02
Drugs
botulinum toxin type b
03
Conditions
sialorrhea
Beyond the preview
Go deeper on NCT01994109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01994109.